# Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

> **NCT02620839** · PHASE1 · TERMINATED · sponsor: **Pamela Munster** · enrollment: 28 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02620839
- **Lead sponsor:** Pamela Munster
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-01-28
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Funding
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620839, "Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT02620839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*